Array Biopharma (ARRY) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.30 -3.23%
Revenue Growth %: -18.0%
Financial Fact:
Cost of revenue: 8.85M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: -18.0%
Financial Fact:
Cost of revenue: 8.85M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.11 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $35.4 million versus the consensus estimate of $32.7 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- UBS Reiterates Neutral Rating on Nike (NKE) on Expected Pace of Earnings Recovery
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
